Project Grant R01DK145458
Award Date 8/1/26
Completion Date 4/30/31
Dollars Obligated $694K
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Rochester, MN 55905, USA
Similar Awards
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Massachusetts General Hospital $835,752 on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop molecular magnetic resonance imaging techniques for non-invasive assessment of inflammatory activity in inflammatory bowel disease. The project aims to create a rapid, sensitive imaging test that evaluates intestinal inflammation anywhere in the...
- Federal Grant Award Summary Mayo Clinic received a $2.84 million Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective September 22, 2025, through September 21, 2029. This award funds research to elucidate the genetic regulation of epithelial injury in ulcerative colitis (UC) and identify predictive biomarkers for anti-tumor necrosis factor...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Mayo Clinic $670,268 on August 15, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate cholangiocyte-driven proinflammatory signaling in primary sclerosing cholangitis (PSC). The research employs spatial analysis of human PSC liver tissues and murine disease models to define how cholangiocytes engage the innate immune system via neutrophil recruitment and...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Brigham and Women's Hospital Inc. $193,776 on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to identify cytokine biomarkers that predict response to IL-23 p19 inhibitor therapies for inflammatory bowel diseases, including Crohn's disease and ulcerative colitis. The research will quantify cytokines related to IL-23 signaling in serum and inflamed...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Mayo Clinic $495,130 on March 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate autophagic processes and hepatocellular steatosis. The award funds research into the mechanisms by which hepatocytes regulate lipid droplet storage, breakdown, and catabolism in metabolic dysfunction-associated steatotic liver disease (MASLD). The research focuses on two...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded the Regents of the University of Michigan $777,956 on March 1, 2026, under CFDA 93.847 (Diabetes, Digestive, and Kidney Diseases Extramural Research) to develop computer vision and machine learning methods for detecting pre-cancerous dysplasia in inflammatory bowel disease patients during colonoscopy and histologic examination. Current detection of dysplasia in IBD patients is hampered by flat, irregular lesions that...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded the University of Washington $825,905 on March 6, 2026, to develop an immunocompetent colon chip platform for modeling Crohn's disease under CFDA 93.847 (Diabetes, Digestive, and Kidney Diseases Extramural Research). The award funds construction of a three-dimensional intestinal platform incorporating primary intestinal and immune cells to model the colonic microenvironment in both health and disease. The platform...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The Washington University $766,951 on April 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop and validate imaging biomarkers for assessing high-risk deceased donor kidneys slated for transplantation. The project addresses kidney shortage by improving the accuracy of kidney quality assessment, reducing the approximately 2,500 procured kidneys discarded...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Mayo Clinic $671,966 on August 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate cholangiocyte pathobiology in primary sclerosing cholangitis. The research addresses PSC pathogenesis and therapeutic targets through examination of cholangiocyte senescence and a proposed viral mimicry mechanism. The project tests the hypothesis that PSC cholangiocytes...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded the Regents of the University of Michigan $687,654 on August 5, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop dynamic contrast-enhanced ultrasound (DCEUS) as a radiation-free alternative to nuclear medicine diuretic renography for diagnosing upper urinary tract obstruction. The research addresses limitations of current diagnostic methods, which expose...